Purpose of review The purpose of the present review is to summarize the potential clinical applications of computed tomographic angiography (CTA) in familial hypercholesterolemia so far and recent advances of CTA research in other high-risk patients.
INTRODUCTION
The FH CTA Consortium is an international group of researchers, who share interest in imaging of the coronary arteries of patients with familial hypercholesterolemia to improve the care for these patients. The main objectives of familial hypercholesterolemia computed tomographic angiography (CTA) are: to study the added value in predicting the outcome (residual risk) of statin-treated familial hypercholesterolemia by imaging of coronary arteries and aortic valves and to determine which factors contribute to atherogenesis in statin-treated familial hypercholesterolemia patients. The Consortium has three strategies to increase the power and the meaningfulness of research with coronary CTA scan images in familial hypercholesterolemia patients: firstly, the largest existing series of patients with familial hypercholesterolemia who underwent CTA will be merged in meta-analyses; secondly, with the lessons learned from the meta-analyses, we will harmonize the clinical databases, the biobanks, and reassess the images in a central imaging core lab; and thirdly, we will perform prospective imaging studies with harmonized standard operating procedures.
Our focus on coronary CTA is based on the availability of coronary images of familial hypercholesterolemia patients, while we acknowledge that there are intriguing technical developments of other noninvasive diagnostic cardiac imaging technologies. Other noninvasive imaging technologies are myocardial perfusion imaging (positron emission tomography, single photon emission computed tomography, and myocardial perfusion scintigraphy), stress echocardiography, and stress perfusion cardiac MRI. Research is needed to optimize the evaluation of familial hypercholesterolemia patients with these techniques and to select the optimal cost-effective strategy. The current literature supports cost-effective strategies using coronary CTA [1] .
The present review is based on a meeting of the FH CTA Consortium on 23 May 2015, in Rotterdam. The participants who contributed to this meeting are listed below this article. This meeting covered a broad range of topics but the purpose of the present review was restricted to summarizing the potential clinical applications of CTA based on the limited CTA findings in familial hypercholesterolemia so far and recent advances of CTA research in other highrisk patients.
CORONARY ARTERY DISEASE IN TREATED FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS
All facets of familial hypercholesterolemia, molecular background, including modifier genes, cardiovascular endpoints, mortality, treatment, and novel treatments have been studied extensively [2] . Still it is very hard to predict the individual residual risk of statin-treated familial hypercholesterolemia patients. The type of referral seems a strong predictor: familial hypercholesterolemia patients, who were identified in a cascade screening program and put on moderate dosages of statins, had a substantially reduced cardiovascular disease risk [3] , whereas asymptomatic familial hypercholesterolemia patients at a lipid clinic on long-term aggressive statin therapy had dramatic aortic, carotid, and coronary atherosclerosis [4] [5] [6] [7] .
Remarkably, little attention has been paid to atherosclerosis of the coronary arteries of treated familial hypercholesterolemia patients. A number of small series of familial hypercholesterolemia patients with CTA scan images have been published (Table 1) [4-6,8,9,10 && ]. These small studies have yielded important information about potential application of coronary CTA in heterozygous familial hypercholesterolemia. Untreated and statintreated familial hypercholesterolemia patients clearly have higher calcium scores as well as a higher plaque burden compared with controls and these differences increase with age [4, 8, 9] . Statin-treated
KEY POINTS
Identification of nonobstructive CAD is of clinical relevance.
The present-day CTA associates with low radiation exposure, has good reproducibility and can be used for follow-up in care as well as in clinical trials.
Aggressively statin-treated, asymptomatic heterozygous familial hypercholesterolemia patients have a huge variation of CAD. The definition of severe familial hypercholesterolemia should also contain information about the coronary arteries.
Treatment strategies for heterozygous familial hypercholesterolemia need to be developed and tested using information of CAC and coronary CTA. familial hypercholesterolemia patients, who are carriers of null alleles of the low-density lipoprotein receptor (LDLR), had higher levels of LDL cholesterol and a higher extent of subclinical coronary atherosclerosis than familial hypercholesterolemia patients with other mutations, that is, mutations with residual LDLR function [6, 9] . Notably, a poor relationship was observed between carotid intimamedia thickness and coronary calcium score and coronary plaque burden [8, 11] . In a meticulous Japanese study, the coronary plaque burden predicted a composite cardiovascular disease endpoint [10 && ]. The current follow-up of the studies in Table 1 is substantial and unpublished additional cohorts of familial hypercholesterolemia patients, who underwent CTA, are available for future analyses of merged data. We need solid information about the diagnostic value of coronary CTA in familial hypercholesterolemia patients, as the performance of contemporary computed tomography systems allows imaging at a significantly reduced radiation exposure, and this imaging technique is more and more applied to evaluate patients with symptoms as well as asymptomatic familial hypercholesterolemia patients.
CORONARY COMPUTED TOMOGRAPHIC ANGIOGRAPHY
CTA is a rapid noninvasive angiographic modality that is widely applied to evaluate chest pain. Coronary artery calcification has been tested most extensively for its use in estimating the cardiovascular prognosis. Coronary calcium clearly provides additive information, above and beyond traditional cardiovascular disease risk evaluations [12, 13] .
In asymptomatic groups of patients with a high cardiovascular disease risk, a strong association between the extent of coronary calcification and clinical outcomes has been observed [10 && , [12] [13] [14] [15] . Interestingly, a small study in a high-risk group, firefighters, showed that coronary calcium predicted increased risk better than traditional cardiovascular disease risk evaluation [16] . These firefighters were relatively young (mean age was 46 years) similar to familial hypercholesterolemia patients who often seek medical attention at relatively young age. CTA is costly and requires contrast medium injection. Therefore, one could argue that screening for coronary artery calcium (CAC) would be a cheap and safe alternative. However, our focus is on CTA, we need to screen persons at a young age because of the inheritance of the disorder. In a small study in asymptomatic patients with type 1 diabetes and young patients with type 2 diabetes (average ages were 26 and 30 years, respectively), we found that CTA is able to detect not yet calcified plaques that would remain undetected on a calcium scan [17] . In a larger study, we extended these findings to older patients with type 2 diabetes and confirmed that, compared with CAC, enhancement of the coronary lumen allows identification of luminal obstruction [18] .
A number of registries have been used to analyze short-term and long-term prognosis of coronary CTA findings in asymptomatic patients [10 && , [12] [13] [14] [15] [16] 19 & ] Recently, a clear association between nonobstructive coronary artery disease (CAD) and allcause mortality was found in the International Multicenter COronary CTA Evaluation For Clinical Outcomes (CONFIRM) registry [20 && ]. A total of 5712 patients had normal coronary arteries and 4706 had nonobstructive CAD. These consecutive patients were followed up for a median of 27 months after CTA for all-cause mortality. The presence and the extent of nonobstructive CAD predicted mortality. Moreover, baseline statin therapy was associated with a significant reduction in mortality for individuals with nonobstructive CAD but not for individuals with normal coronary arteries. Treatment with aspirin showed no influence on all-cause mortality. The findings of CONFIRM suggest that CTA screening of high-risk groups is feasible. The absence of CAC (zero calcium) is associated with a very low risk of future cardiovascular events and it is a guarantee of survival of almost 15 years [21, 22] . The future research of the FH CTA Consortium on clinical decision-making in treated familial hypercholesterolemia will certainly comprise analyses of the absence of CAC in the strategy.
IDENTIFYING SEVERE DISEASE IN FAMILIAL HYPERCHOLESTEROLEMIA
Whether the use of coronary CTA to identify asymptomatic CAD offers a feasible method by which high-risk familial hypercholesterolemia patients can be identified and effectively treated remains unknown. Remarkably, a clear indication for statins, that is, dyslipidemia, has been associated with low mortality risk in CONFIRM [20 && ]. Severe familial hypercholesterolemia tends to be diagnosed based on raised LDL cholesterol levels that are refractory to statin treatment. It might be that identification of severe coronary disease improves the effectiveness of the treatment strategy.
Homozygous familial hypercholesterolemia
Homozygous familial hypercholesterolemia is strongly associated with calcifications of the coronary arteries, the aortic valves as well as the ascending aorta [23] [24] [25] . The modern multimodal treatment with statins and other cholesterol-lowering drugs has improved the survival of these patients, especially when there is some residual LDLR function [26] . The patients with a complete deficiency of LDLR function require LDL apheresis and in the near future, they may profit from lomitapide (microsomal transport protein inhibitor) [27] . LDL cholesterol is an important surrogate marker in research of homozygous familial hypercholesterolemia and full cardiologic follow-up is indicated in this rare extreme familial hypercholesterolemia [28] .
Heterozygous familial hypercholesterolemia
In the quite frequent heterozygous familial hypercholesterolemia, this is completely different. In untreated heterozygous familial hypercholesterolemia, a large variation of mortality has been observed, even among carriers of an identical mutation [29] . In statin-treated heterozygous familial hypercholesterolemia, normalization of CAD risk, severe but asymptomatic CAD as well as myocardial infarction have been observed. So far, a promising biomarker to predict CAD among these treated familial hypercholesterolemia patients has not been identified. Recently, an interesting study was performed in Japanese familial hypercholesterolemia patients, who had signs and symptoms of cardiovascular disease and had relatively often other traditional risk factors of cardiovascular disease [10 && ]. CTA information (coronary plaque burden score based on a 17-segment American Heart Association classification) [30] predicted a composite endpoint of major adverse cardiac events during a median follow-up period of 2.6 years. In 140 asymptomatic, Dutch familial hypercholesterolemia patients, who underwent CTA, only five such events were observed during 5 years (unpublished data). This Dutch group of familial hypercholesterolemia patients clearly had fewer additional risk factors and less affected coronary arteries than the Japanese group. The Japanese study is, however, very promising as it suggests that it is feasible to identify with CTA those familial hypercholesterolemia patients, whose residual CAD risk during statin treatment remains very high.
Severely calcified coronary arteries were observed in asymptomatic familial hypercholesterolemia patients, who were on long-term aggressive statin treatment. These patients had often a high angiographic stenosis burden score as well. Moreover, these coronary abnormalities were strongly associated with age. The findings of these studies suggest that -if heterozygous familial hypercholesterolemia patients were not identified early in a screening program but were referred to a lipid clinic -statin treatment is started too late [4] [5] [6] . An indication for cardiologic follow-up may probably be present as well in these heterozygous familial hypercholesterolemia patients, who although asymptomatic were referred to a specialized center. Moreover, clinical research on a secondary prevention approach should be performed in these familial hypercholesterolemia patients with asymptomatic CAD. Ideally, research with long-term follow-up and repeated CTAs is required to optimize and personalize the treatment of these patients. Immediate CTAs in statin-naïve patients and during statin treatment are needed to examine the effect of long-term aggressive statin treatment on coronary calcification. One might hypothesize that statins increase calcification of plaques as part of the process of stabilizing the plaques [31] .
Heterozygous familial hypercholesterolemia patients, who required CTA to evaluate symptoms, clearly had diffused CAD [8] . In these familial hypercholesterolemia patients at very high CAD risk, the clinical efficacy of statin treatment for secondary prevention may be disappointingly small [32] . Future research with CTA should be considered to test the effect of novel treatment modalities, like PCSK9 inhibitors; in these statin-treated familial hypercholesterolemia patients, whose residual CAD risk remains high. In heterozygous familial hypercholesterolemia, we might need to redefine severe and refractory familial hypercholesterolemia from solely based on LDL cholesterol levels to including information about the CAD state as well. The present-day CTA technology is associated with limited radiation exposure that permits scanning of relatively young familial hypercholesterolemia patients. Notably, coronary calcium was absent in young familial hypercholesterolemia patients with a mean age below 23 years, whereas the peripheral flow-mediated vasodilatation was already impaired suggesting that CTA detects more advanced lesions [33] . In another study with similarly young familial hypercholesterolemia patients, a substantial proportion had coronary calcifications [34] . In the latter study, more additional risk factors were present. The ideal age to start screening with low-dose CTA is unknown and future research is required to develop an optimal cost-effective strategy.
IMPLICATIONS OF COMPUTED TOMOGRAPHIC ANGIOGRAPHY FOR THERAPY
The CTA findings may be of use to intensify lifestyle interventions and to develop strategies that stimulate adherence to therapy [35] . CTA findings may improve the clinical efficacy directly by personalizing the treatment strategies. Especially, severe familial hypercholesterolemia will be deviated from a metabolic surrogate to a potentially more meaningful coronary disease phenotype. This might shift the indication for the novel PCSK9 inhibitors from an LDL cholesterol level to persons with coronary atherosclerotic disease.
There are a number of potential limitations for the use of CTA information in clinical care: CTA measures may not provide unequivocal cut-off values, and the CTA measures may be very variable resulting in wide confidence intervals of the subgroups of patients, who might be at a specific level of CAD risk. Moreover, clinical trials with CTA on which health economic evaluations can be based need to be performed first before implementing CTA-based treatment approaches. Nonetheless, the fact that efficacy of statins could be linked to the subtle forms of CAD in the CONFIRM registry suggest that these CTA trials are feasible.
The necessary cautions should be taken before revascularizations are performed in patients with asymptomatic CAD. In most cases, if not all, ischemia testing should be performed prior to invasive interventions, as the stenoses may be overestimated by CTA, in particular in the presence of calcification [36] . Moreover, hard evidence that screening with imaging in itself saves lives is not available [37, 38] .
IMPLICATIONS OF COMPUTED TOMOGRAPHIC ANGIOGRAPHY FOR CLINICAL TRIALS
We propose to merge CTA data and set up biobanks for drug reposition and target discovery research. Subsequently, the new drugs can be tested in clinical trials using CTA as a surrogate endpoint. The US Food and Drug Administration has previously granted indications for plaque progression as a surrogate endpoint, that is, studies with rosuvastatin and Niaspan, based upon adequate and well controlled clinical trials, which establish that the drug has an effect on atherosclerosis progression. The analysis of the CONFIRM registry established that statins were associated with less CAD resulting in better survival. This study validated subtle CTA-based findings as surrogate endpoint for predicting the most undisputable endpoint, all-cause mortality.
For the new cholesterol-lowering drugs that have been developed recently, CTA might offer a better surrogate endpoint closer to the cardiovascular disease endpoints than LDL cholesterol levels. The reproducibility between scans of coronary plaque volume on coronary CTA is good and can be assessed with automated software [39, 40] . Serial coronary CTA assessments have been successfully applied to follow-up of interventions: for instance, statin treatment, and bio-resorbable stents have been evaluated with coronary CTA [41, 42] .
Moreover, CAC and/or CTA may be used to select patients for clinical studies, that is, to exclude patients with normal coronary arteries. A specific characteristic of trials with CTA is that the endpoints are continuous traits, that is, change of coronary calcification and coronary plaque or stenosis scores, rather than the dichotomous CAD endpoint. Taken together, trials with CTA-based endpoints will require smaller sample sizes, shorter duration, and lower costs compared with randomized clinical trials with hard endpoints. Such smaller and shorter trials may make head to head comparison of drugs more feasible.
CONCLUSION
Research with CTA imaging has made it clear that an increased plaque burden and increased coronary calcium are present even among asymptomatic and long-term aggressively statin-treated familial hypercholesterolemia patients. Clinical trials with CTA are required to develop and test identification of CAD and personalized treatment strategies. If these trials are successful, the definitions of severe and refractory familial hypercholesterolemia should be extended with information about the disease state of the coronary arteries. Familial hypercholesterolemia patients with symptoms of CAD, a history of CAD, extremely high LDL cholesterol levels, or patients who do not respond to statin therapy are at very high risk for CAD and should receive additional preventive therapy, and their LDL cholesterol should be reduced to the target level. However, restricting more extensive treatment to these groups neglects the asymptomatic CAD of a substantial proportion of familial hypercholesterolemia patients who started statin treatment too late, that is, all familial hypercholesterolemia patients who did not start treatment during young adulthood.
The recent findings in the CONFIRM registry are important, because nonobstructive CAD predicted all-cause mortality and statin treatment-reduced CAD and improved the life span. Firstly, this study shows that detection of nonobstructive CAD is clinically relevant instead of a difficult to interpret finding. Secondly, the beneficial effect of statin treatment on coronary atherosclerosis was observed and implicitly the residual risk of treated patients. These findings support the use of CTA in high-risk groups to detect CAD and start preventive measures early. Thirdly, these findings further validate CTA measures as important surrogate endpoints for clinical trials. Trials with CTA will not fully remove the need for clinical outcome trials, but they offer multiple opportunities to speed up the development and reduce the costs of bringing new drugs to the market. Fourthly, head to head comparisons of different preventive strategies may become more feasible. Fifthly, trials with CTA may bring a higher level of evidence to treatment of the rare homozygous familial hypercholesterolemia patients. Finally, if CTA data are merged and combined with biobanks, novel drugs may be discovered that specifically target atherosclerosis.
